Roche Files BLA For Conjugated Herceptin Follow-On Trastuzumab-DM1
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche's next-generation conjugated Herceptin could be on the market for HER2-positive breast cancer patients as soon as the first quarter of 2011, if the application gets a priority review. Roche's wholly owned subsidiary Genentech announced it had filed the trastuzumab-DM1 biologic license application July 7, asking for accelerated approval and a six-month review turnaround
You may also be interested in...
FDA's NME Approval Rebound At Risk: Drought Of Novel Products In Line For Action In Remainder Of 2010 Could Depress Upward Trend From First Half
Almost one-third fewer novel product applications are on FDA’s user fee calendar for the second half of 2010 as compared to the docket at the same point in 2009, a dearth that could imperil the slow but steady improvement in annual new molecular entity and novel biologic approvals after the nadirs reached earlier in the decade.
FDA's NME Approval Rebound At Risk: Drought Of Novel Products In Line For Action In Remainder Of 2010 Could Depress Upward Trend From First Half
Almost one-third fewer novel product applications are on FDA’s user fee calendar for the second half of 2010 as compared to the docket at the same point in 2009, a dearth that could imperil the slow but steady improvement in annual new molecular entity and novel biologic approvals after the nadirs reached earlier in the decade.
ImmunoGen Gains Momentum On Success Of T-DM1, The Herceptin Conjugate In Development By Roche/Genentech
Buoyed by the affirmation of its conjugation technology brought by the imminent filing of T-DM1, ImmunoGen is focused on building an internal pipeline with future emphasis co-development deals, not just outlicensing.